107 College Road East
Princeton, NJ 08540
Tel: 609.608.1246
jcalvarez@drreddys.com

VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov

June 7, 2021

Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

RE: New Prescription Drug – 30-Day Notice

Dear Sir or Madam,

In accordance with 18 V.S.A. § 4637, Dr. Reddy's Laboratories, Inc. provides the following notification:

NDC:	43598-0901-58
Product Description:	Ertapenem for Injection 1g per vial, 10s
Date of Introduction to Market:	5/10/2021
WAC:	$1,000.00 per pack of 10
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Ertapenem for Injection 1g/SDV (Gland Pharma Ltd. ANDA 212040) is being marketed in the generic multi-source space. Establishing the WAC price at $1,000.00 constitutes a significant reduction in the WAC pricing of the referenced listed drug, Invanz, which, upon information and belief, was $1,286.60 at the time Dr. Reddy's introduced Ertapenem for Injection 1g/SDV into the market, representing a 22.3% reduction in price. Dr. Reddy's WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding a prospective Naproxen and Esomeprazole Magnesium Delayed-Release Tablets product; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment.

The estimated volume of patients that may be prescribed the drug	Dr. Reddy's does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy's lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	No
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	No
The date and price of acquisition if the drug was not developed by the manufacturer	NA/NA

Please do not hesitate to contact us if you have any questions.

Regards,

Juan Alvarez

Digitally signed by Juan Alvarez
DN: cn=Juan Alvarez, o, ou, email=jcalvarez@drreddys.com, c=US
Date: 2021.06.07 12:37:28 -04'00'

Juan Alvarez
Government Contracts & Pricing
Dr. Reddy's Laboratories, Inc.